{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:14:10Z","timestamp":1793780050506,"version":"4.6.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Schwann cell tumors are the most common cancers of the peripheral nervous system and can arise in patients with neurofibromatosis type-1 (NF-1) or neurofibromatosis type-2 (NF-2). Functional interactions between NF1 and NF2 and broader mechanisms underlying malignant transformation of the Schwann lineage are unclear. Here we integrate bulk and single-cell genomics, biochemistry, and pharmacology across human samples, cell lines, and mouse allografts to identify cellular de-differentiation mechanisms driving malignant transformation and treatment resistance. We find DNA methylation groups of Schwann cell tumors can be distinguished by differentiation programs that correlate with response to the MEK inhibitor selumetinib. Functional genomic screening in NF1-mutant tumor cells reveals NF2 loss and PAK activation underlie selumetinib resistance, and we find that concurrent MEK and PAK inhibition is effective in vivo. These data support a de-differentiation paradigm underlying malignant transformation and treatment resistance of Schwann cell tumors and elucidate a functional link between NF1 and NF2.<\/jats:p>","DOI":"10.1038\/s41467-024-44755-9","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T06:02:17Z","timestamp":1705039337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9633-1100","authenticated-orcid":false,"given":"Harish N.","family":"Vasudevan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3599-5701","authenticated-orcid":false,"given":"Cyrille L.","family":"Delley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1042-0191","authenticated-orcid":false,"given":"S.","family":"John Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7371-7059","authenticated-orcid":false,"given":"Kanish","family":"Mirchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Sale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Lastella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Sacconi","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calixto-Hope G.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte D.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Casey-Clyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Magill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8924-5853","authenticated-orcid":false,"given":"William C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve E.","family":"Braunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8300-7261","authenticated-orcid":false,"given":"Arie","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa T.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2548-8359","authenticated-orcid":false,"given":"Melike","family":"Pekmezci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R.","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6619-7120","authenticated-orcid":false,"given":"Frank","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-8864","authenticated-orcid":false,"given":"David R.","family":"Raleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"44755_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro Oncol. 24, v1\u2013v95 (2022).","journal-title":"Neuro Oncol."},{"key":"44755_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","volume":"19","author":"M Farid","year":"2014","unstructured":"Farid, M. et al. Malignant peripheral nerve sheath tumors (MPNST). Oncologist 19, 193\u2013201 (2014).","journal-title":"Oncologist"},{"key":"44755_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/neuros\/nyaa455","volume":"88","author":"HN Vasudevan","year":"2021","unstructured":"Vasudevan, H. N., Lucas, C. H. G., Villanueva-Meyer, J. E., Theodosopoulos, P. V. & Raleigh, D. R. Genetic events and signaling mechanisms underlying Schwann cell fate in development and cancer. Neurosurgery 88, 234\u2013245 (2021).","journal-title":"Neurosurgery"},{"key":"44755_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","volume":"54","author":"A Choudhury","year":"2022","unstructured":"Choudhury, A. et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat. Genet. 54, 649\u2013659 (2022).","journal-title":"Nat. Genet."},{"key":"44755_CR5","first-page":"1","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann, D. H. et al. Neurofibromatosis type 1. Nat. Rev. Dis. Prim. 3, 1\u201317 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"44755_CR6","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","volume":"373","author":"AR Asthagiri","year":"2009","unstructured":"Asthagiri, A. R. et al. Neurofibromatosis type 2. Lancet 373, 1974\u20131986 (2009).","journal-title":"Lancet"},{"key":"44755_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/ng.3095","volume":"46","author":"W Lee","year":"2014","unstructured":"Lee, W. et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 46, 1227\u20131232 (2014).","journal-title":"Nat. Genet."},{"key":"44755_CR8","doi-asserted-by":"publisher","unstructured":"De Raedt, T. et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature https:\/\/doi.org\/10.1038\/nature13561 (2014).","DOI":"10.1038\/nature13561"},{"key":"44755_CR9","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/ng.3116","volume":"46","author":"M Zhang","year":"2014","unstructured":"Zhang, M. et al. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Genet 46, 1170\u20131172 (2014).","journal-title":"Nat. Genet"},{"key":"44755_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3171\/2014.7.GKS141311","volume":"121","author":"C Seferis","year":"2014","unstructured":"Seferis, C., Torrens, M., Paraskevopoulou, C. & Psichidis, G. Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate. J. Neurosurg. 121, 160\u2013166 (2014).","journal-title":"J. Neurosurg."},{"key":"44755_CR11","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi, E. et al. Activity of selumetinib in neurofibromatosis type 1\u2013related plexiform neurofibromas. N. Engl. J. Med. 375, 2550\u20132560 (2016).","journal-title":"N. Engl. J. Med."},{"key":"44755_CR12","doi-asserted-by":"publisher","unstructured":"Gross, A. M. et al. Selumetinib in children with inoperable plexiform neurofibromas. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1912735 (2020).","DOI":"10.1056\/NEJMoa1912735"},{"key":"44755_CR13","doi-asserted-by":"crossref","unstructured":"Wu, L. M. N. & Lu, Q. R. Therapeutic targets for malignant peripheral nerve sheath tumors. Fut. Neurol. 14, (2019).","DOI":"10.2217\/fnl-2018-0026"},{"key":"44755_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"Jones Capper","year":"2018","unstructured":"Capper, Jones S. DNA methylation-based classification of central nervous system tumours. Nature 555, 469\u2013474 (2018).","journal-title":"Nature"},{"key":"44755_CR15","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"44755_CR16","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1093\/hmg\/ddz095","volume":"28","author":"SD Rhodes","year":"2019","unstructured":"Rhodes, S. D. et al. Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Hum. Mol. Genet. 28, 2752\u20132762 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"44755_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","volume":"67","author":"MM Miettinen","year":"2017","unstructured":"Miettinen, M. M. et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1\u2014a consensus overview. Hum. Pathol. 67, 1\u201310 (2017).","journal-title":"Hum. Pathol."},{"key":"44755_CR18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/neuonc\/noz028","volume":"21","author":"A Pemov","year":"2019","unstructured":"Pemov, A. et al. Low mutation burden and frequent loss of CDKN2A\/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas. Neuro Oncol. 21, 981\u2013992 (2019).","journal-title":"Neuro Oncol."},{"key":"44755_CR19","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"44755_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-28803-w","volume":"13","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. Fully-automated and ultra-fast cell-type identification using specific marker combinations from single-cell transcriptomic data. Nat. Commun. 13, 1\u201310 (2022).","journal-title":"Nat. Commun."},{"key":"44755_CR21","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"44755_CR22","doi-asserted-by":"publisher","unstructured":"Wassef, M. et al. EZH1\/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer. https:\/\/doi.org\/10.1073\/pnas.1814634116 (2019).","DOI":"10.1073\/pnas.1814634116"},{"key":"44755_CR23","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1002\/cam4.2386","volume":"8","author":"W Qin","year":"2019","unstructured":"Qin, W. et al. TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death. Cancer Med. 8, 5232\u20135241 (2019).","journal-title":"Cancer Med."},{"key":"44755_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41591-019-0376-8","volume":"25","author":"HP Mohammad","year":"2019","unstructured":"Mohammad, H. P., Barbash, O. & Creasy, C. L. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat. Med. 25, 403\u2013418 (2019).","journal-title":"Nat. Med."},{"key":"44755_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.81856","volume":"11","author":"JM Replogle","year":"2022","unstructured":"Replogle, J. M. et al. Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors. Elife 11, 1\u201332 (2022).","journal-title":"Elife"},{"key":"44755_CR26","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","volume":"159","author":"LA Gilbert","year":"2014","unstructured":"Gilbert, L. A. et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159, 647\u2013661 (2014).","journal-title":"Cell"},{"key":"44755_CR27","first-page":"1","volume":"06","author":"SJ Liu","year":"2017","unstructured":"Liu, S. J. et al. CRISPRi-based genome-scale identification of functional long non-coding RNA loci in human cells. Science (1979) 06, 1\u201319 (2017).","journal-title":"Science (1979)"},{"key":"44755_CR28","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1097-2765(03)00382-4","volume":"12","author":"JL Kissil","year":"2003","unstructured":"Kissil, J. L. et al. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol. Cell 12, 841\u2013849 (2003).","journal-title":"Mol. Cell"},{"key":"44755_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrc3645","volume":"14","author":"M Radu","year":"2013","unstructured":"Radu, M., Semenova, G., Kosoff, R. & Chernoff, J. PAK signalling during the development and progression of cancer. Nat. Rev. Cancer 14, 13\u201325 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"44755_CR30","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/hmg\/ddab106","volume":"30","author":"E Hawley","year":"2021","unstructured":"Hawley, E. et al. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2). Hum. Mol. Genet. 30, 1607\u20131617 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"44755_CR31","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2013.08.025","volume":"154","author":"F Yin","year":"2013","unstructured":"Yin, F. et al. Spatial organization of hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin\/NF2. Cell 154, 1342\u20131355 (2013).","journal-title":"Cell"},{"key":"44755_CR32","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.celrep.2018.10.001","volume":"25","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Comprehensive molecular characterization of the hippo signaling pathway in cancer. Cell Rep. 25, 1304\u20131317.e5 (2018).","journal-title":"Cell Rep."},{"key":"44755_CR33","unstructured":"Von Recklinghausen, F. D. Uber ide multiplen Fibrome der Haut und ihre beziehung zu den multiplen Neuromen. Berlin: Hirschwald. 3\u201318 (1882)."},{"key":"44755_CR34","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0092-8674(90)90151-4","volume":"63","author":"R Ballester","year":"1990","unstructured":"Ballester, R. et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63, 851\u2013859 (1990).","journal-title":"Cell"},{"key":"44755_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(90)90150-D","volume":"63","author":"GA Martin","year":"1990","unstructured":"Martin, G. A. et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63, 843\u2013849 (1990).","journal-title":"Cell"},{"key":"44755_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen, W. J. et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin. Investig. 123, 340\u2013347 (2013).","journal-title":"J. Clin. Investig."},{"key":"44755_CR37","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.molcel.2022.03.011","volume":"82","author":"M Chaker-Margot","year":"2022","unstructured":"Chaker-Margot, M. et al. Structural basis of activation of the tumor suppressor protein neurofibromin. Mol. Cell 82, 1288\u20131296.e5 (2022).","journal-title":"Mol. Cell"},{"key":"44755_CR38","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41594-021-00687-2","volume":"28","author":"CJ Lupton","year":"2021","unstructured":"Lupton, C. J. et al. The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1. Nat. Struct. Mol. Biol. 28, 982\u2013988 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"44755_CR39","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-021-04024-x","volume":"599","author":"A Naschberger","year":"2021","unstructured":"Naschberger, A., Baradaran, R., Rupp, B. & Carroni, M. The structure of neurofibromin isoform 2 reveals different functional states. Nature 599, 315\u2013319 (2021).","journal-title":"Nature"},{"key":"44755_CR40","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega, F. et al. Oncogenic signaling pathways in the cancer genome atlas. Cell 173, 321\u2013337.e10 (2018).","journal-title":"Cell"},{"key":"44755_CR41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ccell.2018.01.005","volume":"33","author":"LMN Wu","year":"2018","unstructured":"Wu, L. M. N. et al. Programming of Schwann cells by Lats1\/2-TAZ\/YAP signaling drives malignant peripheral nerve sheath tumorigenesis. Cancer Cell 33, 292\u2013308.e7 (2018).","journal-title":"Cancer Cell"},{"key":"44755_CR42","doi-asserted-by":"publisher","first-page":"9948","DOI":"10.1074\/jbc.RA119.010981","volume":"295","author":"M JA","year":"2020","unstructured":"JA, M. et al. Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1. J. Biol. Chem. 295, 9948\u20139959 (2020).","journal-title":"J. Biol. Chem."},{"key":"44755_CR43","doi-asserted-by":"crossref","unstructured":"Choudhury, A. et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat. Genet. 54, (2022).","DOI":"10.1038\/s41588-022-01061-8"},{"key":"44755_CR44","doi-asserted-by":"crossref","unstructured":"Dehner, C. et al. Chromosome 8 gain is associated with high-grade transformation in MPNST. JCI Insight 6, (2021).","DOI":"10.1172\/jci.insight.146351"},{"key":"44755_CR45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.celrep.2019.08.090","volume":"29","author":"R Sulahian","year":"2019","unstructured":"Sulahian, R. et al. Synthetic lethal interaction of SHOC2 depletion with MEK Inhibition in RAS-driven cancers. Cell Rep. 29, 118\u2013134.e8 (2019).","journal-title":"Cell Rep."},{"key":"44755_CR46","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","volume":"30","author":"MJ Aryee","year":"2014","unstructured":"Aryee, M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30, 1363\u20131369 (2014).","journal-title":"Bioinformatics"},{"key":"44755_CR47","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/bioinformatics\/btw691","volume":"33","author":"JP Fortin","year":"2017","unstructured":"Fortin, J. P., Triche, T. J. & Hansen, K. D. Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi. Bioinformatics 33, 558\u2013560 (2017).","journal-title":"Bioinformatics"},{"key":"44755_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491\u2013498 (2011).","journal-title":"Nat. Genet."},{"key":"44755_CR49","doi-asserted-by":"publisher","unstructured":"Van der Auwera, G. A. et al. From fastQ data to high-confidence variant calls: The genome analysis toolkit best practices pipeline. Curr. Protoc. Bioinf. https:\/\/doi.org\/10.1002\/0471250953.bi1110s43 (2013).","DOI":"10.1002\/0471250953.bi1110s43"},{"key":"44755_CR50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"44755_CR51","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. Fly. (Austin) 6, 80\u201392 (2012).","journal-title":"Fly. (Austin)"},{"key":"44755_CR52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357\u2013360 (2015).","journal-title":"Nat. Methods"},{"key":"44755_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"44755_CR54","first-page":"1","volume":"2","author":"C-HG Lucas","year":"2020","unstructured":"Lucas, C.-H. G. et al. Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival. Neurooncol. Adv. 2, 1\u201312 (2020).","journal-title":"Neurooncol. Adv."},{"key":"44755_CR55","doi-asserted-by":"publisher","unstructured":"Magill, S. T. et al. Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-020-18582-7 (2020).","DOI":"10.1038\/s41467-020-18582-7"},{"key":"44755_CR56","doi-asserted-by":"crossref","unstructured":"Chen, E. Y. et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics (2013).","DOI":"10.1186\/1471-2105-14-128"},{"key":"44755_CR57","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/labinvest.2016.88","volume":"96","author":"H Li","year":"2016","unstructured":"Li, H., Chang, L. J., Neubauer, D. R., Muir, D. F. & Wallace, M. R. Immortalization of human normal and NF1 neurofibroma Schwann cells. Lab. Investig. 96, 1105\u20131115 (2016).","journal-title":"Lab. Investig."},{"key":"44755_CR58","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1016\/j.cell.2022.05.013","volume":"185","author":"Replogle","year":"2022","unstructured":"Replogle et al. Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq. Cell 185, 2559\u20132575 (2022).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44755-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44755-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44755-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T12:04:22Z","timestamp":1705579462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-44755-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["44755"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-44755-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1933793\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"5 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"477"}}